title: Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese.
abstract: BACKGROUND
  Whether rosiglitazone may affect the risk of non-melanoma skin cancer (NMSC) has not been investigated.
  
  
  METHODS
  The reimbursement databases of all Taiwanese diabetic patients from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and a total of 886418 patients with type 2 diabetes were followed up for NMSC incidence until the end of 2009. Incidences for ever-users, never-users and subgroups of rosiglitazone exposure (using tertile cutoffs of duration of therapy and cumulative dose) were calculated and hazard ratios estimated by Cox regression. Additional models were created as sensitivity analyses.
  
  
  RESULTS
  There were 103097 ever-users and 783321 never-users, respective numbers of incident NMSC 250 (0.24%) and 2084 (0.27%), and respective incidence 68.90 and 76.77 per 100000 person-years. Although the overall hazard ratio was not significant in the unadjusted, age-sex-adjusted or fully adjusted model, the risk was significantly lower in the third tertile of duration of therapy and cumulative dose, with significant P for trends. The fully adjusted hazard ratio (95% confidence interval) for a duration of therapy >13.77 months and a cumulative dose of >1752 mg was 0.723 (0.566, 0.923) and 0.783 (0.618, 0.993), respectively. The findings were supported by various sensitivity analyses.
  
  
  CONCLUSIONS
  Rosiglitazone may reduce the risk of NMSC, but further confirmation is required.
authors: Department of Internal Medicine, National Taiwan University College of Medicine, No. 7 Chung-Shan South Road, Taipei, (100), Taiwan. ccktsh@ms6.hinet.net.|Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. ccktsh@ms6.hinet.net.|Division of Environmental Health and Occupational Medicine of the National Health Research Institutes, Taipei, Taiwan. ccktsh@ms6.hinet.net.
authors: Chin-Hsiao
authors: CH
authors: Tseng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D016208:Databases, Factual; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012306:Risk; D000077154:Rosiglitazone; D012878:Skin Neoplasms / Q000453:epidemiology* / Q000517:prevention & control; D013624:Taiwan / Q000453:epidemiology; D045162:Thiazolidinediones / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone
references: Diabetes Care. 2012 Feb;35(2):278-80
references: 22210574
references: Diabetologia. 2012 Mar;55(3):654-65
references: 22127412
references: Metabolism. 2012 Jul;61(7):1003-9
references: 22237115
references: Exp Diabetes Res. 2012;2012:789174
references: 22701472
references: J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30(4):368-402
references: 23167631
references: Pancreas. 2013 Jan;42(1):42-8
references: 22750971
references: BMC Cancer. 2013;13:7
references: 23286275
references: PLoS One. 2012;7(12):e53096
references: 23300866
references: J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2014;32(1):1-45
references: 24598039
references: Mol Carcinog. 2005 Aug;43(4):198-206
references: 15864802
references: Expert Opin Pharmacother. 2005 Aug;6(9):1455-61
references: 16086634
references: Lancet. 2005 Oct 8;366(9493):1279-89
references: 16214598
references: J Pharmacol Exp Ther. 2005 Dec;315(3):996-1004
references: 16109743
references: Cancer Res. 2006 Feb 1;66(3):1873-8
references: 16452250
references: J Invest Dermatol. 2006 Sep;126(9):2002-9
references: 16675962
references: Expert Opin Investig Drugs. 2006 Nov;15(11):1453-68
references: 17040203
references: J Invest Dermatol. 2007 Apr;127(4):935-44
references: 17068478
references: N Engl J Med. 2007 Jun 14;356(24):2457-71
references: 17517853
references: Biochim Biophys Acta. 2007 Aug;1771(8):991-8
references: 17400022
references: Diabetes Care. 2011 Apr;34(4):916-22
references: 21447663
references: Br J Dermatol. 2003 Aug;149(2):229-36
references: 12932225
references: J Invest Dermatol. 2004 Jan;122(1):130-9
references: 14962101
references: Carcinogenesis. 2004 Sep;25(9):1747-55
references: 15073042